2 active not recruiting, 2 completed, 2 recruiting, 1 terminated. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow CT-P6: new trials by email Literature Review of CT-P6 trials Research Report on CT-P6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Recruiting | NRG Oncology | 146 | 2023-03-03 | 2026-10-23 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-23 | 2026-07-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| Evaluate Safety, Efficacy and Pharmacokinetics CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Celltrion | 143 | 2010-02-01 | 2025-01-24 |
Breast Neoplasms (3) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (3) · Celltrion (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (6) · Guam (1) · Puerto Rico (1) · South Korea (1)
Alan L Ho (1) · Investigational Site (1) · Keith T Flaherty (1) · Roisin M Connolly (1) · Senthilkumar Damodaran (1) · Tufia C. Haddad, M.D. (1) · Vicente Valero, MD (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41213241
U10CA180820 (2), P30CA016672 (1), U10CA180868 (1), U24CA196172 (1), UM1CA186688 (1)